CCL17, CCL22 and their receptor CCR4 in hematologic malignancies
Open Access
- 6 September 2024
- journal article
- review article
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-16
Abstract
Hematological malignancies (HM) are common malignant tumors with high morbidity and mortality rates, and are malignant diseases that seriously affect human health, with chemotherapy prone to recurrence and toxic side effects. Therefore, the development of precise, effective, and safe targeted therapeutic agents has become a hotspot in the current research of antitumor technology. More and more studies have shown that the interaction of C–C chemokine ligand 17 (CCL17) and C–C chemokine ligand 22 (CCL22) with the receptor C–C chemokine receptor type 4 (CCR4) promotes the immune escape of tumors and is closely related to the occurrence, development, and prognosis of hematological tumors. In this regard, we present a review on the expression and role of the CCL17/CCL22-CCR4 axis in HM, including lymphoma, leukemia, and multiple myeloma, with the aim of providing latest ideas and directions for the diagnosis and treatment of HM. In addition, we discuss the role and related mechanisms of HM therapeutic agents targeting the CCL17/CCL22-CCR4 axis and the potential of humanized anti-CCR4 antibodies for the treatment of HM.Keywords
Funding Information
- Guizhou Provincial Science and Technology Department (ZK[2021-406])
This publication has 133 references indexed in Scilit:
- Selective Induction of Th2-Attracting Chemokines CCL17 and CCL22 in Human B Cells by Latent Membrane Protein 1 of Epstein-Barr VirusJournal of Virology, 2004
- Increased CCR4 Expression in Cutaneous T Cell LymphomaJournal of Investigative Dermatology, 2002
- Differential Expression of Thymus and Activation Regulated Chemokine and Its Receptor CCR4 in Nodal and Cutaneous Anaplastic Large-Cell Lymphomas and Hodgkin’s DiseaseLaboratory Investigation, 2002
- Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical hodgkin lymphomasInternational Journal of Cancer, 2002
- Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22European Journal of Immunology, 2002
- The CC Chemokines MDC and TARC Induce Platelet Activation Via CCR4Thrombosis Research, 2001
- Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-κBOncogene, 1999
- The T Cell-directed CC Chemokine TARC Is a Highly Specific Biological Ligand for CC Chemokine Receptor 4Journal of Biological Chemistry, 1997
- The immune responses in CD40-deficient mice: Impaired immunoglobulin class switching and germinal center formationImmunity, 1994
- Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes.Journal of Experimental Medicine, 1993